Todd Foley bought $4.2M of Aktis Oncology (AKTS)
Executed Jan 12, disclosed Jan 14, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Jan 14), the stock returned -15.6% (delay-adjusted); from the execution session (Jan 12), -20.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Todd Foley (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Aktis Oncology, Inc. (AKTS). Across 1 priced purchase filing, the average 21-session return was -20.7% from execution and -15.6% from disclosure (delay-adjusted; derived). The largest single filing was $4.2M of AKTS (232,870 sh × $18.00, as filed), executed Jan 12.
Healthcare · Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharm…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→